AbolerIS Pharma is developing a first-in-class monoclonal antibody that induces immune tolerance to treat chronic autoimmune and inflammatory diseases, including transplant rejection and graft-versus-host disease. Their approach aims to restore immune system balance while preserving beneficial immune responses, addressing the challenges of managing these complex conditions.
Funding
$33.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CBSBFounders
Product
Problem
Current treatments for chronic autoimmune and inflammatory diseases, including transplant rejection and graft-versus-host disease, often fail to restore complete immune system balance. These treatments may suppress beneficial immune responses, leading to increased susceptibility to infections and other complications. A more targeted approach is needed to selectively modulate the immune system and preserve its protective functions.
Solution
AbolerIS Pharma is developing a first-in-class monoclonal antibody, ABIS-45RC, designed to induce immune tolerance and re-establish immune homeostasis in patients with chronic autoimmune and inflammatory conditions. The antibody targets CD45RC, a protein expressed on specific immune cells, aiming to selectively eliminate hyperactive T and B cells responsible for driving autoimmune responses. By targeting CD45RC, the therapeutic approach seeks to preserve beneficial immune responses while suppressing pathological inflammation. Preclinical data suggests that ABIS-45RC can effectively control experimental rheumatoid arthritis by eliminating CD45RChigh T and B cells.
Target Audience
The primary target audience includes patients suffering from chronic autoimmune and inflammatory diseases, such as rheumatoid arthritis, transplant rejection, and graft-versus-host disease, as well as clinicians specializing in rheumatology and immunology.
Features
- First-in-class monoclonal antibody targeting CD45RC
- Designed to selectively eliminate hyperactive T and B cells
- Intended to restore immune tolerance and preserve beneficial immune responses
- Preclinical data demonstrating efficacy in controlling experimental rheumatoid arthritis
- GMP production initiated, with plans for CTA submission for FIH studies